AAAAAA
Results:
1-13
|
Results: 13
Authors:
Gion, M
Peloso, L
Mione, R
Vignati, G
Fortunato, A
Saracchini, S
Biasioli, R
Gulisano, M
Cappelli, G
Citation: M. Gion et al., Tumor markers in breast cancer monitoring should be scheduled according toinitial stage and follow-up time: A prospective study on 859 patients, CANCER J, 7(3), 2001, pp. 181-190
Authors:
Gion, M
Mione, R
Leon, AE
Luftner, D
Molina, R
Possinger, K
Robertson, JF
Citation: M. Gion et al., CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases, EUR J CANC, 37(3), 2001, pp. 355-363
Authors:
Dittadi, R
Meo, S
Fabris, F
Gasparini, G
Contri, D
Medici, M
Gion, M
Citation: R. Dittadi et al., Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments, INT J B MAR, 16(2), 2001, pp. 87-96
Authors:
Gasparini, G
Toi, M
Biganzoli, E
Dittadi, R
Fanelli, M
Morabito, A
Boracchi, P
Gion, M
Citation: G. Gasparini et al., Thrombospondin-l and-2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis, ONCOL-BASEL, 60(1), 2001, pp. 72-80
Authors:
Dittadi, R
Gion, M
Citation: R. Dittadi et M. Gion, More about: Prognostic importance of low c-erbB2 expression in breast tumors, J NAT CANC, 92(17), 2000, pp. 1443-1443
Authors:
Gasparini, G
Gion, M
Citation: G. Gasparini et M. Gion, Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints, CANCER J, 6(3), 2000, pp. 117-131
Authors:
Gion, M
Citation: M. Gion, Serum tumour markers: from quality control to total quality management, BREAST, 9(6), 2000, pp. 306-311
Authors:
Gion, M
Mione, R
Barioli, P
Barichello, M
Zattoni, F
Prayer-Galetti, T
Plebani, M
Aimo, G
Terrone, C
Manferrari, F
Madeddu, G
Caberlotto, L
Fandella, A
Pianon, C
Vianello, L
Amoroso, B
Citation: M. Gion et al., Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenario, EUR UROL, 37(4), 2000, pp. 460-469
Authors:
Gion, M
Boracchi, P
Dittadi, R
Biganzoli, E
Peloso, L
Gatti, C
Paccagnella, A
Rosabian, A
Vinante, O
Meo, S
Citation: M. Gion et al., Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possiblyassociated with apoptosis, BREAST CANC, 59(3), 2000, pp. 211-221
Authors:
Gasparini, G
Toi, M
Miceli, R
Vermeulen, PB
Dittadi, R
Biganzoli, E
Morabito, A
Fanelli, M
Gatti, C
Suzuki, H
Tominaga, T
Dirix, LY
Gion, M
Citation: G. Gasparini et al., Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with eitheradjuvant chemotherapy or hormone therapy, CA J SCI AM, 5(2), 1999, pp. 101-111
Authors:
Toi, M
Gion, M
Saji, H
Asano, M
Dittadi, R
Gilberti, S
Locopo, N
Gasparini, G
Citation: M. Toi et al., Endogenous interleukin-12: Relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma, INT J ONCOL, 15(6), 1999, pp. 1169-1175
Authors:
Gion, M
Mione, R
Leon, AE
Dittadi, R
Citation: M. Gion et al., Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer, CLIN CHEM, 45(5), 1999, pp. 630-637
Authors:
Gion, M
Mione, R
Barioli, P
Barichello, M
Zattoni, F
Prayer-Galetti, T
Plebani, M
Aimo, G
Terrone, C
Manferrari, F
Madeddu, G
Caberlotto, L
Fandella, A
Pianon, C
Vianello, L
Citation: M. Gion et al., Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions, CLIN CHEM, 44(12), 1998, pp. 2462-2470
Risultati:
1-13
|